

24/1, SEVASTOPOLSKY PROSPECT
MOSCOW, RUSSIA, 117209
+7 499 744 66 56
WWW.MCCLINICS.COM



MOTHER & CHILD
GROUP OF COMPANIES



HSBC EEMEA & LATAM CONFERENCE 2015

London

September 10, 2015



IMPORTANT NOTICE

The information, statements and opinions contained in this presentation do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of any offer to buy any securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments.

FORWARD-LOOKING STATEMENTS

This presentation contains forward looking statements, which are based on the Company's current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this presentation are based on past trends or activities and should not be taken as a representation that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company's ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.

No statement in this presentation is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement. Except as required by the Listing Rules, the Disclosure and Transparency Rules, the Prospectus Rules, the London Stock Exchange or otherwise by law, the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

1

KEY COMPANY RESULTS
FOR 1H'15

MD MEDICAL GROUP AT A GLANCE


MD Medical Group (“MDMG”) overview

- Russia’s leading private healthcare provider focused on women’s health and paediatrics
- Wide range of medical services including OBGYN¹, fertility and IVF treatment, paediatrics and other services (family medical services, dental care, stem cell storage, laboratory testing and radiology diagnostics)
- Network of modern and high-quality healthcare facilities in Moscow and Russian regions
- Equipment provided by leading international and domestic suppliers
- Highly qualified medical personnel supervised by recognised medical experts

Extensive network across Russian regions



Revenue breakdown, 1H'15




Note: 1 OBGYN – obstetrics and gynaecology
2 calculated as operating profit before depreciation and amortization

Key financial metrics

RUB mln	1H'13	1H'14	1H'15
Revenue	2,578	3,330	4,518
growth, %	31%	29%	36%
EBITDA ²	645	969	1,253
margin, %	25%	29%	28%
Net profit	250	625	768
Net Debt	(273)	3,230	2,096
Net Debt / EBITDA	(0.2x)	1.6x	0.8x

Shareholder structure



Note: Company has GDRs listed on the LSE (Ticker: MDMG LI)

2

OUR MARKET

TRENDS IN THE RUSSIAN PUBLIC HEALTHCARE SYSTEM

Key trends

Federal Budget Shrinkage

“The Government of the Russian Federation under the influence of external factors and economic difficulties forced to accept a reduction of budget expenditures... said Prime Minister Dmitry Medvedev, speaking at the International investment forum”

ITAR-TASS, September 2014

Decrease of Federal Expenditures on Healthcare

“...Federal expenditures on healthcare should be reduced from 169 bln roubles in 2014 to 155 bln roubles in 2015. Projected MHI funding will be 145 billion roubles comparing to 123 billion in the current year.”

RBC, September 2014


High Decrease of Healthcare Expenditures by Moscow Government

“...the decrease in public expenditures on healthcare in both 2013 and 2014 was 10% in real prices, in Moscow - 18%... "Moscow so vigorously reduces healthcare projects, in 2014 they were 4% lower in real prices than in 2011"... Partially due to the transfer of costs to funds of mandatory healthcare insurance.”


RBC, September 2014

PLANS FOR PUBLIC HC SYSTEM DEVELOPMENT IN MOSCOW


Number of public hospitals in Moscow



Reduction of in-patient beds





Reduction of medical staff breakdown by specialization, 2014-2016



PROVIDING SIGNIFICANT GROWTH POTENTIAL OF RUSSIAN FEE-FOR-SERVICE HEALTHCARE SERVICES MARKET

Significant room for further growth – per capita healthcare expenditures*








Market Structure, 2014-2019, bn RUB




Note: * based on data and exchange rates as of 2013
 1 Member countries of the Organisation for Economic Co-operation and Development
 Source: Company data, World Bank 2013; BusinesStat 2014

LIMITED COMPETITION: MDMG IS THE ONLY ESTABLISHED PLAYER FOCUSED ON MATERNITY CARE


Key players in the market

General practices	 <p>MDMG</p>	<p>Focus: Women's health and paediatrics Location: Moscow and Russian regions Number of clinics: 23 (incl. 4 hospitals) Number of in-patient beds: 663</p>
	 <p>Medsis</p>	<p>Focus : General practices Location: Moscow and Russian regions Number of clinics: 30 clinics (incl. 3 hospitals) Number of in-patient beds: 1,153</p>
	 <p>Medicina</p>	<p>Focus: General practices Location: Moscow Number of clinics: 1 hospital Number of in-patient beds: 105</p>
	 <p>GEMC GROUP OF COMPANIES EUROPEAN MEDICAL CENTER EMC</p>	<p>Focus: General practices, trauma Location: Moscow Number of clinics: 2 Number of hospitals: 3</p>
	 <p>СЕМЕЙНЫЙ ДОКТОР СЕТЬ ПОЛИКЛИНИК ДЛЯ ДЕТЕЙ И ВЗРОСЛЫХ Family Doctor</p>	<p>Focus: General practices Location: Moscow Number of clinics: 14</p>
	 <p>Будь Здоров национальный медицинский бренд Bud Zdorov</p>	<p>Focus: General practices Location: Moscow and Russian regions Number of clinics: 10</p>
	 <p>КЛИНИКА «СКАНДИНАВИЯ» Scandinavia</p>	<p>Focus: Women's health, IVF Location: Saint Petersburg and Russian regions Number of clinics: 13 (incl. 1 hospital) Number of in-patient beds: 12</p>

Revenue, 2014



EBITDA, 2014




CASE STUDY: IVF SERVICES IN RUSSIA – HIGHLY ATTRACTIVE SEGMENT OF PRIVATE HEALTHCARE SERVICES

Key aspects


- IVF market in Russia continues to grow with CAGR for 2009 – 2013 of 15%
- Since 2012 government started to provide funding not only for IVF services in public hospitals (federal and regional budgets), but for private healthcare companies as well through MHI system
- General trend seen on the IVF market is reduction of funding provided by federal and regional budgets (only for public hospitals) and growing share of MHI funding. Meaning that private healthcare companies will get more MHI quota for IVF cycles
- It is expected that in 2014 total number of IVF cycles funded by MHI will grow up to 15,000

Number of IVF cycles per 1 million people




IVF cycles in Russia by source of funding

2009-2013 CAGR= 15%



Structure of IVF market covered by out-of-pocket money




3


BUSINESS UPDATE

OPERATIONAL RESULTS 1H'15


Deliveries




IVF cycles



In-patient treatments




Out-patient treatments




Source: unaudited management estimates

OPERATING PERFORMANCE FOR 1H'15


Deliveries




OBGYN in-patient (patient-days)¹



OBGYN out-patient (visits)



IVF (cycles)



Note: 1 OBGYN excl. deliveries
Source: unaudited management estimates

DELIVERIES

- In 1H 2015, the total number of deliveries increased 25% y-o-y to 2,651.
- On a LFL basis the total number of deliveries increased by 1% h-o-h up to 2,140.
- The growth in deliveries at the Group was due to the “Mother and Child Ufa” hospital and consolidating operating indicators of Mother and Child Novosibirsk, in addition to consolidating patient volume at Lapino and PMC.

OBGYN IN-PATIENT TREATMENTS

- The total number of in-patient treatments in 1H'15 increased 19% y-o-y up to 11,710
- LFL patient-days had a marginal decrease of 7% y-o-y to 9,139.
- Drivers of the growth were Ufa hospital, M&C Novosibirsk and Lapino hospital.

OBGYN OUT-PATIENT TREATMENTS


- The total number of OBGYN out-patient treatments in 1H'15 increased by 19% to 220,297 visits.
- Key triggers for the growth were also Ufa, M&C Novosibirsk , Lapino hospital, and better performance of other clinics.

IVF


- The total number of IVF cycles in 1H'15 increased 19% y-o-y to 4,211.
- The overall growth in IVF cycles was primarily due to strong performance of Group's clinics as well as positive effect of consolidation of M&C Novosibirsk .

OPERATING PERFORMANCE FOR 1H'15


Paediatrics in-patient (patient-days)




Paediatrics out-patient (visits)



Other services in-patient (patient-days)



Other services out-patient (visits)



Source: unaudited management estimates

PAEDIATRICS IN-PATIENT TREATMENTS

- The total number of paediatrics in-patient treatments in 1H'15 increased by 49% to 8,259.
- The growth was supported by Ufa hospital and better performance of Lapino and PMC.

PAEDIATRICS OUT-PATIENT TREATMENTS

- The total number of paediatrics out-patient treatments in 1H'15 increased by 27% to 168,143 visits.
- The total increase in out-patient treatments was mostly driven rapid growth in Ufa and Lapino as well consolidation of M&C Novosibirsk .

OTHER MEDICAL SERVICES

- The total number of other medical in-patients treatments (surgery traumatology) in 1H'15 increased by 433% y-o-y to 5,094 due to consolidation of M&C Novosibirsk and Ufa ramp-up while Lapino drove LFL growth.
- The total number of other medical out-patient treatments in 1H'15 increased by 93% y-o-y to 187,330.
- The largest share in other medical out-patient treatments growth was related to M&C Novosibirsk , diagnostic centers at Ufa, Lapino and PMC as well as number of rehabilitation treatments.


4

1H'15 FINANCIAL RESULTS ANALYSIS


KEY FINANCIAL INDICATORS FOR 1H 2015

- The Company increased its revenue and EBITDA in 1H 2015 by 36% and 29% respectively vs. 1H 2014
- In January 2015, the Group increased prices by 10-15% which affected average tickets in 1H'15
- Average ticket for deliveries has also went up due to an increased share of high-price delivery contracts at Lapino and PMC. Average checks at PMC and Lapino increased 14% and 18% correspondingly.
- IVF average tickets grew up by 12% on the back of rising prices for services and medicines since RUB significantly depreciated
- Average check for in- and out-patient services was slightly diluted by regional clinics integrated to the Group due to discounted prices in the regions


Average checks



Revenue



EBITDA & EBITDA margin




REVENUE BRIDGE ANALYSIS

Revenue increased 36% y-o-y to 4,518 mln RUB

- LFL revenue increased by 16% or by 527 mln RUB:
 - For the third year in a row, Lapino became the largest contributor to this revenue increase as a result of continued growth in patient flow, adding 309 mln RUB or 9% to Group revenue
 - Other Group's clinics contributed an additional 7% or 218 mln RUB
- “Mother & child Novosibirsk” (former “Avicenna”) acquired in 4Q 2014 in Novosibirsk, made substantial contribution of 457 mln RUB (+14%) to Group revenue - confirming its important part in Group results
- Ufa hospital added 188 mln RUB to the top-line, demonstrating successful launch and fast growth
- An out-patient clinic in Ryazan opened in February 2015, contributing RUB 16 mln over 5 months of operations

Revenue bridge 1H 2015 vs 1H 2014




Source: 1H 2015 audited financial statements under IFRS

REVENUE STRUCTURE

- The Group's revenue structure saw some changes y-o-y:
 - +7 p.p. increase in other medical services' revenue share (23% vs. 16% as of 1H'14)
 - 5 p.p. decrease in OBGYN ex. deliveries revenue share (24% vs. 29% as of 1H'14)
 - 1 p.p. was lost by both deliveries and paediatrics
- Top-line growth was mostly provided by 3 revenue lines:
 - Deliveries increased by 188 mln RUB, 29% y-o-y
 - IVF grew by 177 mln RUB, 33% y-o-y
 - Other Medical Services' revenue increased by 505 mln RUB, 95% y-o-y
- Other medical services revenue is mostly generated by laboratory examinations, diagnostics centres and surgery

Revenue structure by type of revenue, %



Revenue dynamics by type of revenue, mln RUB


1H 2014	1H 2015	Change, %	Type of revenue	LFL 1H 2014	LFL 1H 2015	Change, %
951	1,094	15% ↑	OBGYN (excl. deliveries)	951	1,013	7% ↑
661	849	29% ↑	Deliveries	661	783	19% ↑
534	711	33% ↑	IVF	534	606	14% ↑
504	642	27% ↑	Paediatrics	504	601	19% ↑
531	1,036	95% ↑	Other medical services	531	670	26% ↑
150	187	24% ↑	Other revenue	150	183	22% ↑
3,330	4,518	36%		3,330	3,857	16%

EBITDA BRIDGE ANALYSIS

EBITDA increased 29% y-o-y to 1,253 mln RUB with a strong margin of 28%

- LFL EBITDA grew up by 25% or by 243 mln RUB. LFL EBITDA margin reached 32%. Key drivers were:
 - Lapino made the most significant contribution to the Group’s EBITDA in 1H 2015, adding 160 mln RUB
 - LFL clinics ex. Lapino added 84 mln RUB
 - Management company expenses were reduced by 3 mln RUB compared to 1H’14
- Newly opened facilities in Ufa and Ryazan were negative in their first reporting periods with 69 mln RUB and 9 mln RUB correspondingly due to ramp-up process
- Mother & child Novosibirsk consisting of 3 clinics and a hospital generated 114 mln RUB of EBITDA with a robust margin of 25%

EBITDA bridge 1H 2015 vs 1H 2014




Source: 1H 2015 audited financial statements under IFRS

x% - EBITDA margin


OPERATING EXPENSES, EXCL. D&A

- Operating expenses (excl. D&A) for 1H 2015 amounted to 3,265 mln RUB, up 38% y-o-y
- LFL OPEX (excl. D&A) increased 12% y-o-y or just 278 mln RUB while LFL revenue rose by 16%
- The largest contributors to OPEX growth were clinics in Novosibirsk and Ufa hospital as well as Lapino where the number of patients continues to grow
- The Company's management saved 3 mln RUB on its costs compared to the corresponding period last year, remaining conservative regarding budget and new expenses

OPEX structure





OPEX (excl. D&A) bridge analysis



COST OF SALES, EXCL. D&A

CoS comparison







- CoS (ex. D&A) amounted to 2,497 mln RUB (+41% y-o-y)
- LFL revenue growth of 16% outperformed LFL CoS growth rate of 14%. LFL CoS amounted to 2,024 mln RUB
- The following costs rose mainly due to the opening of Ufa hospital and consolidation of “Mother & child Novosibirsk”:
 - Payroll costs amounted to 1,624 mln RUB, growing by 36% vs. 1H 2014
 - Materials and supplies demonstrated the fastest growth rate (60% y-o-y) and reached 621 mln RUB which is also explained by RUB depreciation
 - Energy & utilities grew by 45% y-o-y (or 19 mln RUB) up to 61 mln RUB
- Laboratory test expenses increased 26% y-o-y due to an increase in number of tests performed. Corresponding revenue for the period went up by 57%

Revenue and CoS, mln RUB

Indicator	1H 2015	1H 2014	Change y-o-y, %
LFL Revenue	3,853	3,330	+16%
LFL CoS (ex.D&A)	2,024	1,768	+14%
Revenue	4,518	3,330	+36%
CoS (ex. D&A)	2,497	1,768	+41%

G&A, EXCL. D&A

G&A comparison



- Revenue growth rate in 1H 2015 outstripped the G&A growth rate by 6 p.p.
- LFL G&A (excl. D&A) increased 4% or by 22 mln RUB vs. LFL revenue growth of 16%
- The following expenses increased y-o-y due to the opening of a hospital in Ufa and consolidation of facilities in Novosibirsk:
 - Payroll expenses (including social tax expenses) increased by 32% and amounted to 488 mln RUB
 - Utilities and materials grew up by 12 mln RUB y-o-y or 16%
- Other professional services remained almost flat y-o-y at 80 mln RUB (+2% y-o-y)
- Advertising expenses in 1H 2015 grew by 56% due to extensive marketing campaigns for the Ufa hospital and newly opened out-patient clinic in Ryazan

Revenue and G&A, mln RUB

Indicator	1H 2015	1H 2014	Change y-o-y, %
LFL Revenue	3,853	3,330	+16%
LFL G&A(ex.D&A)	615	593	+4%
Revenue	4,518	3,330	+36%
G&A (ex. D&A)	768	593	+30%


Source: 1H 2015 audited financial statements under IFRS

* - In 2014 there was a reclassification between "Payroll" and "Utilities"


CAPEX & CASH FLOW

- Group had solid liquidity position with 1,531 mln RUB in cash & cash equivalents as of 30 June 2015
- OCF amounted to 1,292 mln RUB and increased 31% vs. 1H 2014
- CAPEX cash outflow amounted to 343 mln RUB and was mostly represented as repayment of payables related to investment projects
- Investment cash inflow of 22 mln RUB was related to interest received
- Redemption of bank loans and related finance expenses amounted to 731 mln RUB
- Group managed to return VAT (466 mln RUB) from local authorities paid for Ufa hospital construction. This amount should be annually redeemed in equal parts till 2025

CAPEX Structure



Cash Flow waterfall




* - including proceeds and repayment of borrowings and interest paid
 Source: 1H 2015 audited financial statements under IFRS


WORKING CAPITAL AND NET DEBT

- The Group's debt decreased by 12% to 3,627 mln RUB for 1H 2015
- The Company's cash & cash equivalents amounted to 1,531 mln RUB, representing 72% of growth vs. the corresponding period of the previous year. The significant increase was supported by strong OCF and VAT refund for Ufa hospital.
- Portion of C&CE is being held in foreign currency (mostly USD) in order to minimise effect from volatility of currencies
- The net debt position as of 30 June 2015 was 2,096 mln RUB with net debt to EBITDA* ratio of 0.8x
- The company works with negative working capital as a source of additional financing. Working capital decreased 4% to (1,128) mln RUB from the beginning of the year


Net working capital



Debt




Structure of C&CE by currency



5

OUR STRATEGY

OUR STRATEGY IN ACTION: RECENT DEVELOPMENTS



- Regions with existing clinics and hospitals
- Existing franchised clinics
- Target regions for planned mid-term expansion




STRATEGY IN ACTION: UFA, BASHKORTOSTAN

Key facts about Ufa hospital

- The first Company's hospital outside of the Moscow region
- Total area of 33,000 m² with 192 beds
- A multi-purpose hospital offering a wide range of high-quality services, some of which were not currently available in the republic. List of services include:
 - Deliveries
 - IVF
 - Gynaecology and obstetrics in- and out-patient care
 - Paediatrics in- and out-patient care
 - Neonatology
 - Surgery, urology
 - Stem cell bank

Operational results & average ticket for 1H 2015

Average check for deliveries = 112 kRUB



* - opened in April '15

STRATEGIC VIEW ON COMPANY'S DEVELOPMENT

Factors affecting decision making process

- Exchange rate volatility
- Deterioration of disposable income
- Growing demand for highly-qualified medical care

Strategic view & approach

- Expansion *in* and *to* the regions where people have high disposable income and within Moscow city
- Diversification of hi-tech and high-margin list of services provided

Plans

Moscow :

- Open the new clinic in Moscow M&C Khodynka an IVF department (capacity – 600 cycles annually)
- Open an IVF department in the existing clinic M&C Yugo-Zapad with annual capacity of 1,000 cycles instead of M&C Sokol
- Open a pathohistological laboratory at Lapino with opportunity for extension to immunohistochemistry
- Open a molecular genetics laboratory at PMC

Russian regions:

- Continued ramp-up of Ufa hospital
- Finalising the new design project, construction project documentation and specifications for hospitals in Nizhny Novgorod and Samara. Decision was made to reduce area of new hospitals down to 15,000 – 18,000 sq m in order to make projects less capital intensive.
- Construction of new wing of hospital in Novosibirsk that will adjoin the existing building. Expected to be brought into operation in early 2017. Estimated budget – 1.3 bn RUB. Capacity* - 60 beds, 20 offices, 4 – operation theatres
- Potential M&As in two Russian regions

Appendix



Revenue analysis

	1H2015	1H2014	y-o-y,%
Obstetrics and Gynaecology	1,094	951	+15%
<u>In-patient treatments</u>			
RUB mln	383	335	14%
patient days	11,710	9,848	19%
kRUB per day	32.7	34.0	-4%
% of total*	35%	35%	0 p.p.
<u>Out-patient treatments</u>			
RUB mln	710	616	15%
Admissions	220,297	184,485	19%
kRUB per admission	3.2	3.3	-3%
% of total*	65%	65%	0 p.p.
Deliveries	849	661	28%
RUB mln	849	661	28%
Deliveries	2,651	2,118	25%
kRUB per delivery	320	312	3%
IVF	711	534	33%
RUB mln	711	534	33%
Cycles	4,211	3,529	19%
kRUB per cycles	169	151	12%
Paediatrics	642	504	27%
<u>In-patient treatments</u>			
RUB mln	143	88	63%
Patient-days	8,259	5,526	49%
kRUB per patient day	17.3	15.9	9%
% of total*	22%	17%	+5 p.p.
<u>Out-patient treatments</u>			
RUB mln	499	416	20%
Admissions	168,143	131,395	28%
kRUB per admissions	3.0	3.2	-6%
% of total*	78%	83%	-5 p.p.
Other medical services	1,036	531	95%
<u>In-patient treatments</u>			
RUB mln	213	32	566%
Patient days	5,094	956	433%
kRUB per patient day	41.8	33.5	25%
% of total*	21%	6%	+15p.p.
<u>Out-patient treatments</u>			
RUB mln	391	207	89%
Admissions	187,330	97,007	93%
kRUB per admissions	2.1	2.1	0%
% of total*	38%	39%	-1p.p.
<u>Other medical services</u>			
RUB mln	432	292	48%
% of total*	42%	55%	-13p.p.

- Increase of revenue from OBGYN in-patient treatments by 14% y-o-y is explained by ramp-up at Ufa and consolidation of M&C Novosibirsk. Number of in-patient treatments increased by 19% whilst average check was slightly diluted by regional prices
- Revenue from OBGYN out-patient treatments increased by 15% y-o-y and reached 710 mln RUB. Number of out-patient admissions increased 19% y-o-y since continued growth at Lapino, ramp-up at Ufa and effect from consolidation of M&C Novosibirsk. However, due to lower prices for the Company's services have a discount to Moscow prices. That had a marginal dilutive effect on the average check for OBGYN out-patient treatments
- Revenue from deliveries increased by 28% vs. the corresponding period of last year and reached 849 mln RUB on the back of growing number of deliveries in the Company's hospitals. That was achieved owing to Lapino progress, ramp-up at Ufa and effect from consolidation of M&C Novosibirsk. Average check went up owing to price increase during the period, but that was partially offset by growing number of deliveries in regional facilities.
- Revenue from IVF service line amounted to 711 mln RUB with 33% y-o-y growth. IVF cycles increased +19% y-o-y due to strong performance of existing clinics in Moscow and Russian regions, as well as consolidation of clinics in Novosibirsk. Average check increased 12% due to price indexation
- Revenue from paediatrics in-patient days grew up significantly. Number of paediatric in-patient days increased by 49% y-o-y and amounted to 8,259 on the back of Lapino hospital performance, better results at PMC and new clinics. The average check went up by 9% due to price inflation.
- Revenue from paediatrics out-patient treatments increased 20% to 499 mln RUB while number of in-patient days boosted by 28% up to 168,143 mln RUB owing to new facilities, grown number of patients at Lapino and improved performance of existing clinics. Average ticket decreased 6% due to regional factor.
- Revenue from other medical services in-patient soared up by 6.7x on the back of growing number of patients in general surgery at Lapino, consolidation of M&C Novosibirsk where is big surgery department performing various craniological, urological, oncological surgeries, as well as Ufa results of plastic surgery department. Average ticket grew up to 42 ths RUB.
- Out-patient treatments for other medical services boosted by 93% up to 187,330 mln RUB while revenue grew up to 391 mln RUB (+89%). Revenue is generated by visits to such doctors as urologist, physiotherapists, dentists, cardiologists etc.
- Other medical services revenue is generated by laboratory tests and diagnostics centres. Revenue increased by 48% up-to 432 mln RUB (+48%).

Extract from MDMG's profit and loss statement

(RUB mln)	1H2015	1H2014	1H2013
Revenue	4,518	3,330	2,578
Cost of sales	(2,834)	(1,956)	(1,605)
Gross Profit	1,684	1,374	972
% of revenue	37%	41%	38%
Other income	7	3	2
Administrative expenses	(866)	(632)	(524)
Other expenses	(7)	(3)	(1,7)
EBITDA	1,253	969	645
% of revenue	28%	29%	25%
Operating profit	818	741	448
Net finance expenses	(35)	(71)	(177)
Profit before tax	783	670	271
Tax	(15)	(45)	(21)
Profit for the period	768	625	250
% of revenue	17%	19%	10%
Minority interest	81	57	57
Profit for the year attributable to: shareholders	687	568	428

Extract from MDMG's balance sheet

(RUB mln)	1H2015	FY 2014	FY2013
Cash and cash equivalents	1,531	891	3,273
Investments	3	3	4
Current trade, other receivables and deferred expenses	246	229	152
Inventories	283	268	111
Current tax asset	7	8	8
Assets held for sale	46	46	-
Property, plant and equipment	12,363	12,540	9,210
Non-current trade and other receivables and deferred expenses	64	105	438
Other non-current assets	1,945	1,985	451
TOTAL ASSETS	16,488	16,074	13,648
Current trade and other payables	1,177	899	748
Short term loans and borrowings	1,032	869	618
Other current liabilities	785	788	611
Long term loans and borrowings	2,595	3,251	2,379
Other non-current liabilities	347	131	84
Equity	10,552	10,137	9,209
TOTAL EQUITY AND LIABILITIES	16,488	16,074	13,649
Net Debt	2,096	3,230	(273)

Extract from MDMG's cash flow statement


(RUB mln)	1H2015	1H2014	1H2013
Cash flow from operating activities			
Profit for the period	768	625	250
Adjustments for:			
Depreciation	388	219	192
Taxation	15	45	21
Other adjustments	82	80	186
Cash flow from operations before working capital changes	1,253	969	649
(Increase) / decrease in inventories	(16)	(5)	1,5
Increase in trade and other receivables	(3)	(29)	(17)
Increase in trade and other payables	68	44	65
Increase in deferred income	(3)	45	44
Cash flow from operations	1,299	1,024	742
Tax paid	(7)	(35)	(8)
Net cash flow from operating activities	1,292	988	734
Cash flow from investing activities			
Payment for acquisition of PP&E	(339)	(1,639)	(752)
Withdrawal / (deposit) of investments	-	-	910
Acquisition of subsidiaries	(1)	-	(648)
Other proceeds and payments	20	22	33
Net cash flow used in investing activities	(320)	(1,617)	(457)
Cash flow from financing activities			
GDR Contributions received from underwriters	-	-	150
Proceeds from borrowings	0.5	6	96
Repayment of borrowings	(491)	(271)	(39)
Repayments of obligations under finance leases	(0.1)	(2.3)	(1.6)
Proceed from reimbursed VAT	466	-	-
Finance expenses paid	(240)	(158)	(166)
Other payments	-	(3)	-
Dividends paid to the owners of the Company	-	(180)	(314)
Dividends paid to non-controlling interests	(58)	(80)	(35)
Net cash flow from financing activities	(323)	(688)	(308)
Net increase in cash and cash equivalents	649	(1,317)	(32)
Cash and cash equivalents at the beginning of the period	891	3,273	2,583
Effect due to exchange rate changes	(8)	68	120
Cash and cash equivalents at the end of the period	1,531	2,024	2,671

CONTACTS



24/1, SEVASTOPOLSKY PROSPECT
MOSCOW, RUSSIA, 117209

WWW.MCCLINICS.COM



Elena Romanova

Head of Investor Relations

+7 495 331 41 20

e.romanova@mcclinics.ru

Sofia Denisova

IR Manager

+7 495 331 43 57

s.denisova@mcclinics.ru